Monoamine oxidase A and B inhibitors in Parkinson's disease

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 93-120

  Youdim, Moussa B H ^a   Riederer, Peter F ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Clinic and Policlinic for Psychiatry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649513919     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84034-6     Document Type: Chapter

References (180)

1. Abassi Z.A., Binah O., and Youdim M.B. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol 143 3 (2004) 371-378
2. Adolfsson R., Gottfries C.G., Oreland L., et al. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27 (1980) 1029-1034
3. Akao Y., Maruyama W., Yi H., et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326 2 (2002) 105-108
4. Akao Y., Maruyama W., Shimizu S., et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82 4 (2002) 913-923
5. Allain H., Pollak P., and Neukirch H.C. Symptomatic effect of selegiline in de novo parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 8 Suppl 1 (1993) 36-40
6. Amrein R., Martin J.R., and Cameron A.M. Moclobemide in patients with dementia and depression. Adv Neurol 80 (1999) 509-519
7. Angst J., Amrein R., and Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta analysis and prospective studies. J Clin Psychopharmacol 15 (1995) 16S-23S
8. Bar-Am O., Yogev-Falach M., Amit T., et al. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89 5 (2004) 1119-1125
9. Bar-Am O., Amit T., and Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355 3 (2004) 169-172
10. Bar-Am O., Weinreb O., Amit T., et al. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19 13 (2005) 1899-1901
11. Benecke R. Diffuse Lewy body disease-a clinical syndrome or a disease entity?. J Neurol 250 Suppl 1 (2003) I39-I42
12. Biagini G., Zoll M., Fuxe K., et al. L-deprenyl increases GFAP immunoreactivity selectively in inactivated astrocytes in rat brain. Neuroreport 5 (1993) 955-958
13. Biagini G., Frasoldati A., Fuxe K., et al. The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes. Neurochem Int 25 (1994) 17-22
14. Bijl D. The serotonin syndrome. Neth J Med 62 9 (2004) 309-313
15. Birkmayer W., Riederer P., Youdim M.B., et al. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36 (1975) 303-326
16. Birkmayer W., Riederer P., Ambrozi L., et al. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1 (1977) 439-443
17. Birkmayer W., Knoll J., Riederer P., et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64 2 (1985) 113-127
18. Blandini F., Armentero M.T., Fancellu R., et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 187 2 (2004) 455-459
19. Blum-Degen D., Müller T., Kuhn W., et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer' and de novo Parkinson's disease patients. Neurosci Lett 202 (1996) 17-20
20. Bonneh-Barkay D., Ziv N., and Finberg J.P. Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology 48 3 (2005) 406-416
21. Borbe H.O., Niebch G., and Nickel B. Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in rat. J Neural Transm Suppl 32 (1990) 131-137
22. Bosboom J.L., and Wolters E. Psychotic symptoms in Parkinson's disease: pathophysiology and management. Expert Opin Drug Saf 3 3 (2004) 209-220
23. Bridge T.P., Soldo B.J., Phelps B.H., et al. Platelet monoamine oxidase activity: demographic characteristics contribute to enzyme activity variability. J Gerontol 40 (1985) 23-28
24. Buccafusco J.J., Terry A.J., Goren Jr. A.V., et al. Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 119 3 (2003) 669-678
25. Buys Y.M., Trope G.E., and Tatton W.G. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 14 (1995) 119-126
26. Cesura A.M., and Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 38 (1992) 171-297
27. Chan-Palay V. Depression and senile dementia of Alzheimer's type: a role for moclobemide. Psychopharmacology 106 (1992) S137-S139
28. Churchyard A., Mathias C.J., Boonkongchuen P., et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 63 2 (1997) 228-234
29. Clarke A., Johnson E.S., Mallard N., et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 110 11 (2003) 1257-1271
30. Clarke A., Brewer F., Johnson E.S., et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110 11 (2003) 1241-1255
31. Collins G.G., Sandler M., Williams E.D., et al. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225 (1970) 817-820
32. Da Prada M., Keller H., Keller R., et al. Ro 11-1163, a specific short acting MAO inhibitor with antidepressant properties. Monoamine Oxidase. Basic and Clinical Frontiers (1981), Excerpta Medica, Amsterdam 183-196
33. Da Prada M., Zürcher G., Wuthrich I., et al. On tyramine, food beverages and reversible MAO inhibitor moclobemide. J Neural Transm Suppl 26 (1988) 31-56
34. Eliash S., Shteter N., and Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm 112 8 (2005) 991-1003
35. Erfurth A.B., and Back T. Severe therapy refractory depression as initial mainstream of Parkinson's disease. Psychiatr Prax 26 (1999) 46-47
36. Finberg J.P., and Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77 1 (1982) 13-21
37. Finberg J.P., and Youdim M.B. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43 7 (2002) 1110-1118
38. Finberg J.P., Tenne M., and Youdim M.B. Tyramine antagonistic properties of AGN 1135, and irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73 (1981) 65-74
39. Finberg J.P., Lamensdorf I., Commissiong J.W., et al. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl 48 (1996) 95-101
40. Finberg J.P., Wang J., Bankiewicz K., et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl 52 (1998) 279-285
41. Finberg J.P., Takeshima T., Johnston J.M., et al. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9 (1998) 703-707
42. Finberg J.P., Lamensdorf I., Weinstock M., et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 80 (1999) 495-499
43. Finnegan K.T., Skratt J.J., Irwin I., et al. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184 (1990) 119-126
44. Foley P., Gerlach M., Youdim M.B.H., et al. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?. Parkinsonism Rel Disord 6 1 (2000) 2547
45. Fowler C.J., Oreland L., Marcusson J., et al. Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil. Naunyn Schmiedebergs Arch Pharmacol 311 (1980) 263-272
46. Gerlach M., Riederer R., Przuntek R., et al. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208 (1991) 273-286
47. Gerlach M., Reichmann H., and Riederer P. "Die Parkinson-Krankheit" (2003), Grundlagen, Klinik Therapie. Unter Mitarbeit von W. Götz und U. Sommer. Dritte, überarbeitete und erweiterte Auflage. XVII 368 Seiten
48. Gibson C.J. Inhibition of MAO-B, but not MAO-A, blocks DSP-4 toxicity on central NE neurons. Eur J Pharmacol 141 (1987) 135-138
49. Glover V., and Sandler M. Neurotoxins and monoamine oxidase B inhibitors: possible mechanisms for the neuroprotective effect of (-)-deprenyl. In: Szelenyi I. (Ed). Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical use in Neurodegenerative Disorders (1993), Birkhäuser, Basel 169-181
50. Goetz C.G., Koller W.C., Poewe W., et al. Treatment intervention for Parkinson's disease: an evidence based assessment. Mov Disord 17 4 (2002) 38-39
51. Green A.R., and Grahame-Smith D.G. In: Grahame-Smith D.G. (Ed). Handbook of Psychopharmacology Vol. 3 (1975), Plenum, New York 350-388
52. Green A.R., and Youdim M.B. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol 55 3 (1975) 415-422
53. Green A.R., Mitchell B.D., Tordoff A.F., et al. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60 3 (1977) 343-349
54. Haefely W., Burkard W.P., Cesura A.M., et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl) 106 (1992) S6-S14
55. Haefely W., Burkard W.P., Cesura A., et al. Pharmacology of moclobemide. Clin Neuropharmacol 16 Suppl 2 (1993) S8-S18
56. Hallman H., and Jonsson G. Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP4 on central noradrenaline neurons. Eur J Pharmacol 103 3-4 (1984) 269-278
57. Izumi T., Iwamoto N., Kitaichi Y., et al. Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats. Eur J Pharmacol 532 3 (2006) 258-264
58. Jansen Steur E.N., and Ballering L.A. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Adv Neurol 80 (1999) 505-509
59. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17 (1968) 1285-1297
60. Kalir A., Sabbagh A., and Youdim M.B. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase A and B. Br J Pharmacol 73 (1981) 55-64
61. Knoll J. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm Suppl 25 (1987) 45-66
62. Knoll J., and Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5 (1972) 393-408
63. Konradi C., Kornhuber J., Froelich L., et al. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 33 2 (1989) 383-400
64. Konradi C., Kornhuber J., Sofic E., et al. Variations of monoamines and their metabolites in the human brain putamen. Brain Res 579 2 (1992) 285-290
65. Korn A., Da Prada M., Raffesberg W., et al. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm Suppl 26 (1988) 57-71
66. Koutsilieri E., Chen T.S., Rausch W.D., et al. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylopyridinium. Eur J Pharmacol 306 (1996) 181-186
67. Kragten E., Lalande I., Zimmermann K., et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273 (1998) 5821-5828
68. Lamensdorf I., Youdim M.B., and Finberg J.P. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67 4 (1996) 1532-1539
69. Larsen J.P., Boas J., and Erdal J.E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol 6 (1999) 539-547
70. Lauterbach E.C. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 27 4 (2004) 801-825
71. Le W., Jankovic J., Xie W., et al. (-)-Deprenyl protection of 1-methyl-4-phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett 224 (1997) 197-200
72. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 11 Suppl 5 (1997) S10-S21; discussion S37-S39
73. Leentjens A.F. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 17 3 (2004) 120-126
74. Lees A.J., Shaw K.M., Kohout L.L., et al. Deprenyl in Parkinson's disease. Lancet 2 8042 (1977) 791-795
75. Magyar K. Pharmacology of monoamine oxidase type B inhibitors. In: Szelenyi I. (Ed). Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders (1993), Birkhäuser, Basel 125-143
76. Magyar K. Behaviour of (-)-deprenyl and its analogues. J Neural Transm Suppl 41 (1994) 167-175
77. Magyar K.B., Szende J., Lengyel J., et al. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm 52 Suppl (1998) 109-123
78. Mally J., Kovacs AB., and Stone TW. Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. J. Neurol. Sci. 134 (1995) 143-145
79. Mann J., and Gershon S. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26 (1980) 877-882
80. Mann J.J. A controlled study of antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46 (1989) 45-50
81. Marek K.L., Friedman J., Hauser R., et al. Phase II evaluation of rasagiline mesylate (TVP-1012), a novel anti-parkinsonian drug, in parkinsonian patients not using levodopa/carbidopa. Mov Disord 12 (1997) 838-846
82. Maruyama W., Akao Y., Youdim M.B., et al. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78 4 (2001) 727-735
83. Maruyama W., Akao Y., Carrillo M.C., et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24 5 (2002) 675-682
84. Maruyama W., Weinstock M., Youdim M.B., et al. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341 3 (2003) 233-236
85. Maruyama W., Nitta A., Shamoto-Nagai M., et al. N-Propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44 6 (2004) 393-400
86. Marzo A., Dal Bo L., Monti N.C., et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 50 1 (2004) 77-85
87. Mendlewicz J., and Youdim M.B. Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor. J Neural Transm 43 (1978) 279-286
88. Mendlewicz J., and Youdim M.B.H. Anti-depressant potentiation of 5-hydroxytrytophan by l-deprenyl in affective disorder. J Aff Disord 2 (1979) 137-146
89. Mendlewicz J., and Youdim M.B.H. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiatry 142 (1983) 508-511
90. Mosimann U.P., and McKeith I.G. Dementia with Lewy bodies-diagnosis and treatment. Swiss Med Wkly 133 9-10 (2003) 131-142
91. Mössner R., Henneberg A., Schmitt A., et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 6 3 (2001) 350-352
92. Murphy D.L., Wright C., Buchsbaum M., et al. Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16 (1976) 254-265
93. Müller T., Kuhn W., Krüger R., et al. Selegiline as immunostimulant-a novel mechanism of action?. J Neural Transm Suppl 52 (1998) 321-328
94. Myllylä VV., Sotaniemie KA., Vuorinen J.A., and Heinonen E.H. Neurology 42 (1992) 339-343
95. Mytilineou C., Radcliffe P.M., and Olanow C.W. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 68 (1997) 434-436
96. Mytilineou C., Radcliffe P., Leonardi E.K., et al. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68 (1997) 33-39
97. Naoi M., Maruyama W., Youdim M.B., et al. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 11 2 (2003) 175-181
98. Nieuwstraten C., Labiris N.R., and Holbrook A. Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 51 5 (2006) 300-316
99. O'Carroll A.M., Fowler C.J., Phillips J.P., et al. The deamination of dopamine by human brain monoamine oxidase. Arch Pharmacol 322 (1983) 198-223
100. Olanow C.W., Hauser R.A., Gauger L., Malaparia T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., and Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol 38 (1995) 771-777
101. Palhagen S., Heinonen E.H., and Hagglund J. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. J Neurol 51 (1998) 520-525
102. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 321 (1989) 1364-1371
103. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann. Neurol. 33 (1993) 350-356
104. Parkinson Study Group. Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease. New Engl. J. Med. 328 (1993) 176-183
105. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59 12 (2002) 1937-1943
106. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 4 (2004) 561-566
107. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62 2 (2005) 241-248
108. Paterson I.A., and Tatton W.G. Antiapoptotic actions of monoamine oxidase B inhibitors. Adv Pharmacol 42 (1998) 312-315
109. Paterson I.A., Boulton A.A., and Juorio A.V. Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission. J Neural Transm Suppl 29 (1990) 119-129
110. Paterson I.A., Zhang D., Warrington R.C., et al. R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem 70 (1998) 515-523
111. Paykel E., and Youdim M.B.H. Monoamine oxidase inhibitors: new developments. Clin Neuropharmacol 16 Suppl 2 (1993) 96-212
112. Priest R.G. Moclobemide: a range of opportunities. Psychopharmacology (Berl) 106 (1992) S140-S141
113. Przuntek H., and Kuhn W. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J. Neural Transm 25 (1987) 97-104
114. Przuntek H., Conrad B., and Dichgans J. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. J. Neurol. 6 (1999) 141-150
115. Rascol O., Brooks D.J., Melamed E., et al. LARGO Study Group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 9463 (2005) 947-954
116. Ravikumar R., Lakshmana M.K., Rao B.S., et al. (-)-Deprenyl attenuates spinal motor neuron degeneration and associated locomotor deficits in rats subjected to spinal cord ischemia. Exp Neurol 149 (1998) 123-129
117. Revuelta M., Venero J.L., Machado A., et al. Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes. Glia 21 (1997) 204-216
118. Riederer P., and Lachenmayer L. Selegiline's neuroprotective capacity revisited. J Neural Transm 110 11 (2003) 1273-1278
119. Riederer P., and Youdim M.B.H. Human brain monoamine oxidase activity and monoaminemetabolism in Parkinsonian patients treated with L-deprenyl. J Neurochem 45 (1986) 1349-1356
120. Riederer P., Konradi C., Schay V., et al. Location of MAO-A and MAO-B in human brain, a step in understanding the therapeutic action of L-deprenyl. Adv Neurol 45 (1986) 111-119
121. Riederer P., Lachenmayer L., and Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 11 (2004) 2033-2043
122. Rihmer Z., Seregi K., and Rihmer A. Parkinson's disease and depression. Neuropsychopharmacol Hung 6 2 (2004) 82-85
123. Roy E., and Bédard P.J. Deprenyl increases survival of rat foetal nigral neurones in culture. Neuroreport 4 (1993) 1183-1186
124. Sagi Y., Weinstock M., and Youdim M.B. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 86 2 (2003) 290-297
125. Sagi Y., Mandel S., Amit L., et al. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25 1 (2006) 35-44
126. Salo P.T., and Tatton W.G. Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31 (1992) 394-400
127. Sautter J., Gerlach M., Schwarz J., et al. TVP-1012, an irreversible MAO-B-inhibitor protects against MPTP-neurotoxicity in the monkey-comparison with deprenyl. 11th International Symposium on Parkinson's Disease, Rome, March 26-30 (1994)
128. +) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures. J Neural Transm 104 (1997) 875-885
129. Semokova I., Wolz P., Schilling M., et al. Selegiline enhances NGF synthesis and protects central nervous system (CNS) neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315 (1996) 19-30
130. Seniuk N.A., Henderson J.T., Tatton W.G., et al. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J Neurosci Res 37 (1994) 278-286
131. Shoulson I., Oakes D., and Fahn S. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. J. Ann. Neurol. 51 (2002) 604-612
132. Sieradzan K., Chanon S., Stern G., et al. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. Clin Psychopharmacol 15 (1995) 51S-60S
133. Singer T.P., and Ramsay R.R. The interaction of monoamine oxidases with tertiary amines. Biochem Soc Trans 19 (1991) 211-215
134. Sivertsen B., Dupont E., and Mikkelsen B. Selegiline and levodopa in early of moderately advanced Parkinson's disease: a double-blind controlled short- and longterm study. E. Acta Neurol. Scand. 126 (1989) 147-152
135. Speiser Z., Katzir O., Rehavi M., et al. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav 60 (1998) 387-393
136. Speiser Z., Levy R., and Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 52 (1998) 287-300
137. Sprague J.E., and Nichols D.E. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology (Berl) 118 (1995) 357-364
138. Sternic N., Kacar A., Filipovic S., et al. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease. Clin Neuropharmacol 21 (1998) 93-96
139. Sterling J., Tamas T., Toth G., et al. Novel dual inhibitors of AChE and MAO derived from hydroxyl aminoindan and phenetylamine as potential treatment for Alzheimer's disease. J Med Chem 45 24 (2002) 5260-5279
140. Stocchi F., Arnold G., Onofrj M., et al. Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology 63 4 (2004) 746-748
141. Szeleny I. Inhibitors of Monoamine Oxidase B. (1993), Birkhäuser, Boston
142. Tatton W.G., and Chalmers-Redman R.M. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47 Suppl 3 (1996) S171-S183
143. Tatton W.G., Ju W.Y., Holland D.P., et al. (-)-Deprenyl reduces PC12 apoptosis by inducing new protein synthesis. J Neurochem 63 (1994) 1572-1575
144. Tatton W.G., Wadia J.S., Ju W.Y., et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm 48 (1996) 45-59
145. Tetrud J.W., and Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. J. W. Science 245 (1990) 519-522
146. Thiffault C., Lamarre-Theroux L., Quirion R., et al. L-deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Mol Brain Res 44 (1997) 238-244
147. Vaglini F., Pardini C., Cavalletti M., et al. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effects of 1-methyl-4-phenylpyridinium ion. Brain Res 741 (1996) 68-74
148. Wadia J.S., Chalmers-Redman R.M., Ju W.J., et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 18 (1998) 932-947
149. Waters C.H., Sethi K.D., Hauser R.A., et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19 (2004) 426-432
150. Weinreb O., Bar-Am O., Amit T., et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18 12 (2004) 1471-1473
151. Weinstock M., Bejar C., Wang R.H., et al. TV 3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm Suppl 60 (2000) 157-169
152. Weinstock M., Kirschbaum-Slager N., Lazarovici P., et al. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann NY Acad Sci 939 (2001) 148-161
153. Weinstock M., Poltyrev T., Bejar C., et al. Effect of TV 3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) 160 3 (2002) 318-324
154. Weinstock M., Gorodetsky E., Wang R.H., et al. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology 43 6 (2002) 999-1005
155. Weinstock M., Gorodetsky E., Poltyrev T., et al. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 27 4 (2003) 555-561
156. Wild R., Pettit T., and Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 3 (2003) CD003672
157. Wilfried K., Müller T., Kruger R., et al. Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6. Neuroreport 7 (1997) 2847-2848
158. Williams K., Romano C., Dichter M.A., et al. Modulation of the NMDA receptor by polyamines. Life Sci 48 (1991) 469-498
159. +dopaminergic toxicity. J Neural Transm 100 (1995) 53-61
160. Wu R.M., and Murphy DL and Chiueh C.C. Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline). Ann NY Acad Sci 786 (1996) 379-390
161. Yogev-Falach M., Amit T., Bar-Am O., et al. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 17 15 (2003) 2325-2327
162. Youdim M.B.H. Reversible and Selective Inhibitors of Monoamine Oxidase: New Findings. Acta Psyuchiat, Scand 91 (1995) 1-43
163. Youdim M.B., and Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26 1 (2005) 27-35
164. Youdim M.B., and Buccafusco J.J. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm 111 (2005) 519-537
165. Youdim M.B., and Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm 91 (1993) 181-195
166. Youdim M.B., and Riederer P. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Mov Disord 8 Suppl 1 (1993) S8-S13
167. Youdim M.B., and Weinstock M. Molecular basis of neuroprotective activities of rasagaline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate.]. Cell Mol Neurobiol 21 6 (2001) 555-573
168. Youdim M.B.H., and Sourkes T.L. The effect of heat, pH and riboflavin deficiency on monoamine oxidase activity. Can J Biochem 43 (1965) 1305-1318
169. Youdim M.B., Collins G.G., Sandler M., et al. Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature 236 (1972) 225-228
170. Youdim M.B.H., Green A.R., and Grahame-Smith D.G. The role of 5-hydroxytryptamine, dopamine and MAO in the production of hyperactivity. In: Birkmayer W., and Hornykiewicz O. (Eds). Advances in Parkinsonism (1976), Editiones Roche, Base l155-l163
171. Youdim M.B.H., Finberg J.P.M., and Tipton K.F. Monoamine oxidase. In: Trendelengurg U., and Weiner U. (Eds). Catecholamine II (1988), Springer-Verlag, Berlin 119-192
172. Youdim M.B.H., Da Prada M., and Amrein R. The cheese effect and new reversible MAO-A inhibitors. J Neural Transm Suppl 26 (1988)
173. Youdim M.B., Gross A., and Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132 2 (2001) 500-506
174. Youdim M.B., Wadia A., Tatton W., et al. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition cell culture and in vivo. Ann NY Acad Sci 939 (2001) 450-458
175. Youdim M.B., Amit T., and Falach-Yogev M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol 66 8 (2003) 1635-1641
176. Youdim M.B., Maruyama W., and Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41 6 (2005) 369-391
177. Youdim M.B.H., Edmondson D., and Tipton K.F. Monoamine oxidases. Nat Rev Neurosci 7 (2006) 295-309
178. Yu P.H., Davis B.A., Fang J., et al. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63 (1994) 1820-1828
179. Zappia V., and Pegg A.E. Progress in Polyamine Research (1998), Plenum Press, New York
180. Zhang X., Zuo D.M., Davis B.A., et al. Immunohistochemical evidence of